APTO News and Press, Aptose Biosciences Inc. From 08/04/20

CG-806 Phase 1 a/b Study in B Cell Malignancies Advances to Fifth (750mg) Dose Cohort FDA Allows IND for Phase 1 a/b Study of CG-806 in AML to Initiate at 450mg Dose Level APTO-253 Phase 1b Study in AML / MDS Advances to Fifth (150mg/m 2 ) Dose Cohort Conference Call and Webc...

SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30...

Tricida (NASDAQ: TCDA )   -33%  after FDA flags deficiencies in Veverimer. More news on: Tricida, Inc., INmune Bio, Inc., WISeKey International Holding AG, Stocks on the move, , Read more ...

Aptose Biosciences (NASDAQ: APTO ) has priced its public offering of 10.5M common shares at $5.25/share, for expected gross proceeds of ~$55M. More news on: Aptose Biosciences Inc., Healthcare stocks news, , Read more ...

Aptose (NASDAQ: APTO ) commences a public offering of its common shares. More news on: Aptose Biosciences Inc., Healthcare stocks news, Read more ...

Aptose Biosciences (NASDAQ: APTO ) is up  7%  premarket in reaction to its announcement that the FDA has signed off on its IND application to initiate a Phase 1a/b clinical study of CG-806, an oral FLT3/BTK inhibitor, in patients with acute myeloid leukemia (AML). More news on:...

Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML Phase 1a/b study in B-cell malignancies continues through dose escalation SAN DIEGO and TORONTO, June 29, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS),...

Biotech  has outpaced nearly every other sector this year in growth. While the S&P 500 was down 3.6% for the year as of Wednesday, the NASDAQ Biotechnology Index (NBI) is up 10.5% in 2020. That growth carries an enormous amount of risk, however, as many biotech companies aren't mak...

New clinical data on Aptose Biosciences' (NASDAQ: APTO ) CG-806, an oral, FLT3/BTK cluster selective kinase inhibitor, was presented at the 25 th Congress of the European Hematology Association. More news on: Aptose Biosciences Inc., Healthcare stocks news, Stocks on the move, Read ...

Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies Plasma from CG-806 treated patients completely inhibited phospho-FLT3, suggesting current dose levels may be therapeutic in patients with AML New IN...